RSVpreF

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

COVID-19Respiratory Syncytial Virus (RSV)RSV Infection

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

1

RSVpreF

Pfizer

Approved

12

Singulair

AstraZeneca

Preclinical

13

Rayaldee

OOrganon and Co

Preclinical

14

Proventil

Mylan Pharmaceuticals Inc

Preclinical

15

Aquasol E

NNational Eye Institute (NEI)

Preclinical

16

Nitrostat

VViatris Specialty LLC

Preclinical

17

SARS-COV-2 VACCINE

Moderna

Preclinical

28

Achromycin V

WWyeth-Lederle Vaccines

Preclinical

—9

Statins

Sanofi

Preclinical

110

Antihypertensive Agents

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

1Show 7 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Immunogenicity5 trials

A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults.

Completed·Pfizer·Phase 3·NCT06473519·453 enrolled

Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age

Completed·Pfizer·Phase 3·NCT05301322·1,471 enrolled

A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea

Completed·Pfizer·Phase 3·NCT06593587·378 enrolled

Show 2 more trials

A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease

Completed·Pfizer·Phase 3·NCT05842967·885 enrolled

Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.

Active, not recruiting·Pfizer·Phase 3·NCT05035212·38,861 enrolled

Respiratory Syncytial Virus (RSV)2 trials

A Study to Examine Respiratory Combination Vaccines Against Respiratory Syncytial Virus (RSV) and Flu in Older Adults

Completed·Pfizer·Phase 1·NCT05788237·508 enrolled

A PHASE 3 STUDY IN INDIA TO DESCRIBE THE SAFETY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS

Not yet recruiting·Pfizer·Phase 3·NCT07653100·540 enrolled

Adult1 trial

Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age

Completed·Pfizer·Phase 3·NCT05096208·1,028 enrolled

Aged1 trial

SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDER

Active, not recruiting·Pfizer··NCT06546800·1,100 enrolled

Children1 trial

A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age

Completed·Pfizer·Phase 1·NCT05900154·128 enrolled

7 more indications

Pregnant Women1 trial

SPECIAL INVESTIGATION FOR ABRYSVO IN PREGNANT WOMEN AND INFANTS

Active, not recruiting·Pfizer··NCT06482099·497 enrolled

Pregnancy1 trial

A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.

Completed·Pfizer·Phase 3·NCT04424316·14,727 enrolled

COVID-191 trial

A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).

Completed·Pfizer·Phase 2·NCT05886777·1,142 enrolled

Vaccination1 trial

Study of RSVpreF Vaccination and RSV Challenge in Healthy Adults

Completed·HHvivo·Phase 2·NCT04785612·70 enrolled

RSV Infection1 trial

A Phase 3 Study to Investigate the Safety, Tolerability, and Immunogenicity of Revaccinating Pregnant Participants During Subsequent Pregnancies and Persistence of Immunity of a Single Dose of a Bivalent Respiratory Syncytial Virus (RSV) Vaccine.

Recruiting·Pfizer·Phase 3·NCT06866405·550 enrolled

RSV Immunization1 trial

Study of HIV-Exposed Pregnancies and Transplacental Antibody Delivery Following RSVpreF (SHIELD-RSV)

Not yet recruiting·UUniversity of British Columbia·Approved·NCT07693166·20 enrolled

Respiratory Syncytial Virus1 trial

A PHASE 3, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN PREGNANT PARTICIPANTS LIVING WITH HIV AND THEIR INFANTS

Completed·Pfizer·Phase 3·NCT06325657·681 enrolled

Details

Drug Info

Related News